HC Wainwright Has Strong Forecast for LXRX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Lexicon Pharmaceuticals to a loss of $0.14 per share from a loss of $0.15, versus the analyst consensus loss of $0.16.
• Lexicon reported a quarterly loss of $0.03 per share, narrower than the $0.06 loss analysts expected, while revenue of $11.25 million topped estimates of $4.14 million.
• Analysts overall rate LXRX a “Hold,” with an average price target of $5.70. Investors are also watching for SONATA-HCM Phase 3 trial results, expected in Q1 2027.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright increased their FY2026 EPS estimates for shares of Lexicon Pharmaceuticals in a report released on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($0.14) for the year, up from their previous forecast of ($0.15). The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals' FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.17) EPS and FY2030 earnings at ($0.09) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $4.14 million. Lexicon Pharmaceuticals had a negative return on equity of 35.76% and a negative net margin of 161.80%.

A number of other equities research analysts have also issued reports on LXRX. Cantor Fitzgerald assumed coverage on Lexicon Pharmaceuticals in a research report on Monday, September 28th. They issued an "overweight" rating and a $8.00 price target on the stock. Wall Street Zen raised Lexicon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Sunday. Weiss Ratings reissued a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Finally, Zacks Research lowered shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $5.70.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX opened at $1.78 on Monday. Lexicon Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $2.68. The firm has a market cap of $792.03 million, a PE ratio of -12.71 and a beta of 1.10. The company has a current ratio of 10.62, a quick ratio of 10.56 and a debt-to-equity ratio of 0.32. The stock has a fifty day moving average price of $1.81 and a 200 day moving average price of $1.89.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $27,000. Squarepoint Ops LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $28,000. Pictet Asset Management Holding SA acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth about $41,000. Bank of New York Mellon Corp raised its position in shares of Lexicon Pharmaceuticals by 43.6% during the 1st quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company's stock worth $43,000 after acquiring an additional 8,335 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Lexicon Pharmaceuticals during the third quarter worth approximately $66,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Key Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon posted a Q3 loss of $0.03 per share, narrower than the $0.06 loss analysts expected and the $0.04 loss a year earlier. Revenue of $11.25 million also topped estimates of about $4.14 million. Zacks earnings report
• Positive Sentiment: The Phase 3 SONATA-HCM trial is substantially overenrolled, with top-line results expected in Q1 2027. This could provide a significant upcoming clinical catalyst. Lexicon clinical and financial update
• Positive Sentiment: Lexicon said positive STENO1 safety data strengthen the benefit-risk profile for a ZYNQUISTA NDA resubmission, potentially advancing another path to value creation. Lexicon clinical and financial update
• Neutral Sentiment: Phase 1 clinical development of LX9851 is ongoing at Novo Nordisk; the update indicates continued progress but offered no new results or specific timeline. Lexicon clinical and financial update
• Negative Sentiment: Despite beating estimates, Lexicon still reported a quarterly loss, reflecting continued profitability risk as investors await clinical and regulatory progress.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon's commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.